Alvaro Lenze Julia's questions to Grifols SA (GRFS) leadership • Q2 2024
Question
In a follow-up, Alvaro Lenze Julia asked about the drivers of strong Albumin performance, requesting an update on related clinical trials. He also asked for clarification on a EUR 27 million EBITDA adjustment related to the Shanghai RAAS stake.
Answer
CEO Nacho Abia attributed the strong Albumin performance to demand from China, where Grifols is well-positioned, and noted that top-line results for the PRECIOSA study in liver cirrhosis are expected in Q4. VP of IR Daniel Segarra directed the question on the specific EBITDA adjustment to the report's annexes for a full reconciliation.